Effect of Pretreatment Platelet Parameters on Survival in Limited Disease Small Cell Lung Cancer

Abstract

Background:The aim of this study was to investigate the effect of platelet parameters before concurrent chemoradiotherapy (CCRT) on survival of patients with limited disease small cell lung cancer (LD-SCLC). Methods: This study consisted of patients who received CCRT due to LD-SCLC in the oncology clinic between 1997-2017. Examined platelet parameters included total platelet count (TPC), mean platelet volume, platelet distribution width, and platelet-lymphocyte ratio. The cut-off value for TPC was determined as 306x10 9 /U (sensitivity: 62%, specificity: 75.5%), where patients below or equal to this level was classified as Group I, and those above as Group II. Results:The study included 90 patients whose mean age was 59 years (range: 42-83) and male ratio was 80.0% (n=72). Near three-fourths of patients (74.4%) were at clinical stage III. Among stage I-II patients, mOS was found as 126 months for Group I whereas it had not been reached in Group II (p=0.158). Stage III patients showed significantly lower mOS for Group 1 (16 [range: 14.1-17.8] months) compared to that in Group 2 (19.0 [range: 15.6-62.8] months; p=0.002). In multivariate analysis, Eastern Cooperative Oncology Group performance score (p=0.003), clinical stage (p<0.001), prophylactic cranial irradiation (p=0.004), and TPC (p=0.031) was determined as the most significant factors affecting survival. Conclusion: Our study suggests association of high baseline levels of TPC to improved survival in patients scheduled to undergo CCRT for LD-SCLC. Considering easiness and universal availability of TPC measurement, potential utilization of this biomarker may be promising to predict survival, albeit requiring validation by further well-designated prospective studies.

Inflammation scores as prognostic biomarkers in small cell lung cancer: a systematic review and meta-analysis

“…In summary, all included studies were retrospective studies published between 2008 and 2020. The majority of studies were conducted in Asia ( n = 23) [ 17 , 21 , 23 – 25 , 27 – 30 , 32 , 33 , 36 – 38 , 41 – 44 , 46 – 49 ], primarily China, whereas eight studies [ 16 , 22 , 26 , 31 , 34 , 35 , 50 , 51 ] originated from Europe and two from the USA [ 39 , 40 , 45 ]. A total of 7762 patients with SCLC were included with the number of patients included in each study ranging from 46 to 938.…”

“…A total of 7762 patients with SCLC were included with the number of patients included in each study ranging from 46 to 938. In more than half of the studies ( n = 19) [ 17 , 21 , 23 – 25 , 27 – 30 , 33 , 36 , 37 , 41 , 42 , 44 , 45 , 48 – 50 ], the included patients were a mixture of patients with limited disease (LD) and patients with extended disease (ED), whereas only patients with LD were included in eight studies [ 16 , 26 , 31 , 34 , 40 , 43 , 46 , 47 ] and only patients with ED were included in five studies [ 32 , 35 , 38 , 39 , 51 ]. For one study, the stage of disease was not described [ 22 ].…”

“…The median/mean age of included patients varied from 56 to 72 years, and 6–50% of the included patients were female. Smoking was assessed in 26 studies [ 21 , 23 – 27 , 29 – 34 , 36 , 38 – 48 , 50 , 51 ] demonstrating that 28–100% of the patients had a history of smoking. Furthermore, the performance status was estimated in 26 studies [ 16 , 17 , 21 – 27 , 29 , 32 – 34 , 36 , 38 – 40 , 42 – 45 , 47 – 51 ] demonstrating that 33–100% of the patients were in a good performance defined by Eastern Cooperative Oncology Group Performance Status < 2 or Karnofsky performance scale ≥ 80.…”

“…Furthermore, the performance status was estimated in 26 studies [ 16 , 17 , 21 – 27 , 29 , 32 – 34 , 36 , 38 – 40 , 42 – 45 , 47 – 51 ] demonstrating that 33–100% of the patients were in a good performance defined by Eastern Cooperative Oncology Group Performance Status < 2 or Karnofsky performance scale ≥ 80.…”

Inflammation Scores as Prognostic Biomarkers in Small Cell Lung Cancer: A Systematic Review and Meta-Analysis

“…In the identi ed 33 studies, an adjusted risk estimate of mortality risk between patients with a low versus a high score could only be retrieved in 25 studies (NLR: 16 (17,21,22,24,25,29,32,35,41,(43)(44)(45)(46)(49)(50)(51), PLR: 7 (24,25,34,37,41,50,51), LMR: 2 (21,41), MLR: 2 (46,47), mGPS:4 (28,30,34,39), SII: 3 (24,40,41), ALI:1 (23,26)). Rating and adjustment variables for the individual study are listed in Table 1.…”